Back to News
Market Impact: 0.25
J&J's RYBREVANT FASPRO Regimen Delivers 77% Response Rate In First-Line HNSCC Study
Source: Nasdaq
Healthcare & Biotech
Johnson & Johnson reported deep and durable responses in Cohort 5 of the Phase 1b/2 OrigAMI-4 study of first-line subcutaneous amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO), combined with a PD-1 inhibitor and fixed-duration carboplatin. The excerpt provides no response rates, follow-up duration, or other numerical results, limiting assessment of the data’s clinical and market significance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
JNJ0.55
More News
- Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
- Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer
- Ex-PepsiCo CEO Indra Nooyi worked from midnight until 5 a.m. as a receptionist to pay for her Yale degree—and she says ‘respect went up’ because of it
- Xencor reports phase 1 data for cancer drug XmAb819
- ArriVent reports phase 1 data for cancer drug ARR-217